Dermatology

November 22nd 2024

This meta-analysis showed that both secondary closure techniques substantially reduce the risk of hidradenitis suppurativa recurrence compared to primary direct closure.

November 21st 2024

The investigators concluded that chronic psychological stress substantially impacts skin homeostasis and, consequently, skin aging.

November 20th 2024

UCB has announced the FDA’s approval of bimekizumab, also known as Bimzelx, for patients with moderate-to-severe HS.

November 19th 2024

These data were announced by Protagonist Therapeutics, resulting from the 2 pivotal ICONIC-LEAD and ICONIC-TOTAL studies on the oral peptide icotrokinra.